The present invention relates to a production method of a crystal of (R)-lansoprazole or (S)-lansoprazole, which includes crystallization at a temperature of about 0 DEG C to about 35 DEG C from a C1-4 alkyl acetate solution containing (R)-lansoprazole or (S)-lansoprazole at a concentration of about 0.1 g/mL to about 0.5 g/mL and the like. According to the production method of the present invention, a crystal of (R)-lansoprazole or (S)-lansoprazole superior in preservation stability can be produ...

It is intended to provide preparations such as capsules containing an acid-unstable medicament (in particular, a benzimidazole compound having an antiulcer effect, etc.) at a high concentration which are prepared by using about 12% by weight or more (based on the total granules) of the acid-unstable chemical and blending a basic inorganic salt therewith to give granules of about 600 [mu]m or more in the average particle size.

The present invention relates to a production method of a crystal of (R)-lansoprazole or (S)-lansoprazole, which includes crystallization at a temperature of about 0(C to about 35(C from a C1-4 alkyl acetate solution containing (R)-lansoprazole or (S)-lansoprazole at a concentration of about 0.1 g/mL to about 0.5 g/mL and the like. According to the production method of the present invention, a crystal of (R)-lansoprazole or (S)-lansoprazole superior in preservation stability can be produced effi...

Disclosed is a tablet which comprises an acid-unstable physiologically active substance as an active ingredient, which has the same level of hardness as that of a conventional tablet, and which can exhibit an excellent quick-disintegrating property even in the presence of a small quantity of water. Specifically disclosed is a tablet which can be suspended in water upon use. The tablet comprises an enteric coated fine granule comprising an acid-unstable physiologically active substance and an add...

The present invention relates to a production method of a crystal of (R)-lansoprazole or (S)-lansoprazole, which includes crystallization at a temperature of about 0(C to about 35(C from a C1-4 alkyl acetate solution containing (R)-lansoprazole or (S)-lansoprazole at a concentration of about 0.1 g/mL to about 0.5 g/mL and the like. According to the production method of the present invention, a crystal of (R)-lansoprazole or (S)-lansoprazole superior in preservation stability can be produced effi...

The present invention relates to a production method of a crystal of (R)-lansoprazole or (S)-lansoprazole, which includes crystallization at a temperature of about 0 DEG C. to about 35 DEG C. from a C1-4 alkyl acetate solution containing (R)-lansoprazole or (S)-lansoprazole at a concentration of about 0.1 g/mL to about 0.5 g/mL and the like. According to the production method of the present invention, a crystal of (R)-lansoprazole or (S)-lansoprazole superior in preservation stability can be p...

An injectable composition comprising a combination of 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (lansoprazole), its optically active compound or a salt thereof, and a chelating agent, which is used at pH 9 to 12. The injectable composition is excellent in stability and solubility, and has such a high-quality that particulate insolubles are not formed when the composition is kept and supplied in a glass container and even in a plastic container and also...

An injectable composition comprising a combination of 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (lansoprazole), its optically active compound or a salt thereof, and a chelating agent, which is used at pH 9 to 12. The injectable composition is excellent in stability and solubility, and has such a high-quality that particulate insolubles are not formed when the composition is kept and supplied in a glass container and even in a plastic container and also...

An injectable composition comprising a combination of 2-[[[3-methyl-4-(2,2,2 - trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (lansoprazole ), its optically active compound or a salt thereof, and a chelating agent, whic h is used at pH 9 to 12. The injectable composition is excellent in stability and solubility, and has such a high-quality that particulate insolubles are not formed when the composition is kept and supplied in a glass container an d even in a plastic container and...